Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Inovio Pharmaceuticals, Inc. - Common Stock (NQ: INO )

2.080 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 134
Open 2.080
Bid (Size) 2.110 (5)
Ask (Size) 2.140 (8)
Prev. Close 2.080
Today's Range 2.080 - 2.080
52wk Range 1.740 - 14.75
Shares Outstanding 210,356,896
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What's Going On With Inovio Pharmaceuticals (INO) Stock?
Shares of Inovio Pharmaceuticals pulled back by 5.3% during Wednesday's session. The decline may be attributed to profit-taking, as investors assess renewed focus on respiratory illnesses. 
Via Benzinga
Why Inovio Pharmaceuticals (INO) Stock Is Skyrocketing
Inovio Pharmaceuticals shares are trading higher by 20.7% Tuesday afternoon. Vaccine stocks are rising amid growing concerns about respiratory illnesses. 
Via Benzinga

Performance

YTD
+14.29%
+14.29%
1 Month
+16.20%
+16.20%
3 Month
-63.76%
-63.76%
6 Month
-80.30%
-80.30%
1 Year
-74.94%
-74.94%

More News

Read More
Top 3 Health Care Stocks That Could Blast Off This Month
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Gold Down Over 1%; Inovio Pharmaceuticals Shares Plummet
Via Benzinga
Crude Oil Gains Over 1%; RH Shares Jump On Strong Forecast
Via Benzinga
Exposures Fossil Fuels
The Analyst Landscape: 4 Takes On Inovio Pharmaceuticals
Via Benzinga
A Preview Of Inovio Pharmaceuticals's Earnings
Via Benzinga
The Analyst Verdict: Inovio Pharmaceuticals In The Eyes Of 4 Experts
Via Benzinga
US Stocks Mixed; Broadcom Shares Surge On Upbeat Earnings
Via Benzinga
Why Inovio Pharmaceuticals (INO) Stock Is Down 40%
Via Benzinga
US Stocks Likely To Open Higher, Investors Eye Fed Policy Meet Next Week: Broadcom, RH, Costco In Focus
Via Benzinga
Topics Economy
Exposures Interest Rates
Why RH Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Via Benzinga
RH, Broadcom And 3 Stocks To Watch Heading Into Friday
Via Benzinga
European And US Vaccine Stocks Are Under Pressure - Here's WHy
Via Benzinga
Exposures Product Safety
Inovio Pharmaceuticals (INO) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
Via FinancialNewsMedia
Exposures COVID-19
Earnings Scheduled For November 14, 2024
Via Benzinga
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
From FN Media Group LLC
Via GlobeNewswire
Inovio Pharmaceuticals (INO) Q2 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
INO Stock Earnings: Inovio Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Better Buy: Inovio Pharmaceuticals vs. Novavax
Via The Motley Fool
Why Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
DNA Medicine Focused INOVIO Pharma Efficiencies Implemented By Leadership Will Help De-Risk Its Platform Technology: Analyst
Via Benzinga
Exposures Product Safety
Inovio Pharmaceuticals (INO) Q1 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.